Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Gets Coverage from DoD for Cologuard Screening Test

NEW YORK (GenomeWeb) – Exact Sciences announced today that its Cologuard colon cancer screening test is now covered by Tricare, the healthcare program of the US Department of Defense.

All 9.4 million active duty, reserve, and National Guard personnel, as well as veterans and their dependents, are now covered to use Cologuard every three years without patient coinsurance, copayments, or deductibles, Exact said. This policy decision brings Tricare's screening policies in line with the preventive services coverage mandate of the Affordable Care Act.

In an advisory notice to Congress, Tricare added that the decision to cover Cologuard also falls in line with recommendations from the United States Preventive Services Task Force. "Collectively, these changes will revise Tricare colon cancer screening provisions to allow coverage of stool DNA testing (e.g., Cologuard) once every 3 years beginning at the age of 50 for individuals at average risk of colon cancer based on the USPSTF's most recent recommendations," Tricare noted.

Coverage became effective on June 21.

"Cologuard is the ideal patient-friendly colon cancer screening option for America's active military and veterans to use at home, ensuring they can efficiently be screened for the most preventable form of cancer," said Exact Chairman and CEO Kevin Conroy in a statement. "Ensuring Cologuard is available to those who serve our country and their families with no out-of-pocket cost through Tricare is a critical step toward increasing colon cancer screening."

This decision is one of several positive coverage policies Exact has received for Cologuard in recent months. In August, the company said Cologuard would be covered by Health Care Services and Florida Blue, as well as Medicare Advantage plans.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.